Drug intelligence / Profile preview

CCP-06

Development stage: Preclinical
Lead developer: Tris Pharma
Administration: Oral

Overview

CCP-06 is a product developed through a collaboration between Vernalis and Tris Pharma. It leverages Tris Pharma's OralXR+ sustained-release liquid formulation technology and is intended for the US prescription cough and cold market as an extended-release liquid treatment.

Beyond the preview

Go deeper on CCP-06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCP-06.

Explore the full profile